Actively Recruiting
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
Led by Rush University Medical Center · Updated on 2026-01-08
604
Participants Needed
1
Research Sites
383 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
As tranexamic acid (TXA) becomes more prevalent, all patients are receiving the same dose and method of delivery regardless of their pre-operative risk of transfusion. Therefore, the aim of the study is to determine whether or not repeated dosing of oral or different method of delivery like intravenous (IV) TXA reduces the postoperative reduction in hemoglobin, hematocrit, number of transfusions, and postoperative blood loss following open spine surgery. The regimen that utilizes multiple doses of oral TXA will significantly minimize post-operative blood loss and transfusion requirements compared to the use of a single dose regimen. Furthermore, oral TXA will be as efficacious as intravenous delivery of TXA.
CONDITIONS
Official Title
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient is older than 18 years old
- Scheduled for an open posterior thoracolumbar spinal fusion procedure
You will not qualify if you...
- Allergy to tranexamic acid (TXA)
- Acquired disturbances of color vision
- Refusal of blood products
- Use of anticoagulant therapy within five days before surgery
- History of arterial or venous thromboembolic disease such as DVT, PE, CVA, or TIA
- Pregnancy
- Breastfeeding
- Severe ischemic heart disease (New York Heart Association Class III or IV)
- Previous myocardial infarction
- Severe pulmonary disease
- Renal impairment
- Hepatic failure
- Patient declines to participate
- Intolerance or sensitivity to Vitamin C
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Rush University Medical Center
Chicago, Illinois, United States, 6060712
Actively Recruiting
Research Team
M
Matthew Colman, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here